Clinical Trials
13 trialsNCT07616141 2026-06-01
NAET4-SNACC
Eye & ENT Hospital of Fudan University
Phase 2 Not yet recruiting
NCT07612098 2026-05-28
SPARE-04
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT07602101 2026-05-22
Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma
RenJi Hospital
Phase 2 Not yet recruiting
NCT07562581 2026-05-01
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 2 Not yet recruiting
NCT07540390 2026-04-22
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT07545213 2026-04-22
Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 2 Not yet recruiting
NCT07538258 2026-04-20
Aurora004
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT07538271 2026-04-20
Aurora 005
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT07537777 2026-04-17
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT07501169 2026-04-13
STAR-01
Sichuan University
Phase 2 Not yet recruiting
NCT07470840 2026-03-24
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT07489300 2026-03-24
BACON
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT07320963 2026-03-20
Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.
Sun Yat-sen University
Phase 1/2 Not yet recruiting